2025 was a challenging year for the UK biotech sector, but it ended the year with signs of "renewed confidence and broadening investor appetite." That is the conclusion of the annual assessment of the ...
The first data has emerged on the uptake of Novo Nordisk's new oral version of GLP-1 agonist weight-loss therapy Wegovy, with encouraging signs of strong demand as a potential rival from Eli Lilly ...
The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox. Follow us for the latest industry news and insights.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results